As the field of targeted therapeutic radiopharmaceuticals evolves, the story no longer focuses solely on beta-emitting lutetium-177, which is widely used in targeted therapy to destroy cancer cells while sparing healthy tissue. Alpha emitters have gained attention for their ability to emit more powerful radiation and induce double-stranded DNA breaks.
In Where It’s 211At: The Potential of Astatine-211 as a Therapeutic Radionuclide, published September 2, 2026, Andy Hsieh, Ph.D., partner and biotech research analyst, provides investors with an outline of astatine-211, including its production methods and supply chain, companies developing astatine-211 programs, and clinical trials evaluating its therapeutic potential.
To learn more about William Blair’s biotech equity research, contact us or your William Blair representative.